Zacks Investment Research downgraded shares of Dova Pharmaceuticals (NASDAQ:DOVA) from a hold rating to a sell rating in a research note released on Wednesday, Zacks.com reports.

According to Zacks, “Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company’s drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. “

DOVA has been the subject of a number of other reports. HC Wainwright increased their price target on shares of Dova Pharmaceuticals from $18.00 to $39.00 and gave the stock a buy rating in a research note on Thursday, June 27th. BidaskClub upgraded shares of Zillow Group from a buy rating to a strong-buy rating in a report on Tuesday, July 2nd. Wedbush set a $190.00 price objective on shares of Home Depot and gave the stock a hold rating in a report on Wednesday, May 22nd. Finally, Evercore ISI upgraded shares of Dova Pharmaceuticals from an in-line rating to an outperform rating and set a $15.00 price objective on the stock in a report on Monday, July 1st. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. Dova Pharmaceuticals has an average rating of Buy and an average price target of $28.56.

DOVA stock opened at $16.99 on Wednesday. Dova Pharmaceuticals has a 1 year low of $5.62 and a 1 year high of $26.49. The company has a market capitalization of $472.90 million, a P/E ratio of -6.53 and a beta of 2.56. The business has a 50-day moving average of $11.35. The company has a current ratio of 4.46, a quick ratio of 4.27 and a debt-to-equity ratio of 0.20.

Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.10. Dova Pharmaceuticals had a negative net margin of 521.67% and a negative return on equity of 87.20%. The company had revenue of $4.00 million during the quarter, compared to the consensus estimate of $3.46 million. As a group, equities research analysts anticipate that Dova Pharmaceuticals will post -2.1 earnings per share for the current year.

In other Dova Pharmaceuticals news, insider Lee F. Md Phd Allen sold 1,957 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $14.19, for a total value of $27,769.83. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Life Sciences Maste Perceptive acquired 427,209 shares of the business’s stock in a transaction on Friday, June 28th. The stock was acquired at an average price of $13.35 per share, for a total transaction of $5,703,240.15. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 582,854 shares of company stock worth $8,243,825 and sold 18,838 shares worth $284,611. 60.30% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp grew its holdings in Dova Pharmaceuticals by 4.9% in the fourth quarter. Bank of New York Mellon Corp now owns 49,907 shares of the company’s stock worth $378,000 after purchasing an additional 2,313 shares during the period. DekaBank Deutsche Girozentrale grew its holdings in shares of Dova Pharmaceuticals by 22.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 13,300 shares of the company’s stock valued at $336,000 after buying an additional 2,400 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Dova Pharmaceuticals by 46.1% during the fourth quarter. Rhumbline Advisers now owns 15,343 shares of the company’s stock valued at $116,000 after buying an additional 4,843 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Dova Pharmaceuticals by 14,705.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 5,034 shares of the company’s stock valued at $38,000 after buying an additional 5,000 shares during the last quarter. Finally, Birchview Capital LP grew its holdings in shares of Dova Pharmaceuticals by 25.0% during the first quarter. Birchview Capital LP now owns 50,000 shares of the company’s stock valued at $445,000 after buying an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 30.18% of the company’s stock.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Featured Article: What are retained earnings?

Get a free copy of the Zacks research report on Dova Pharmaceuticals (DOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.